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The role of healthcare providers in HPV vaccination programs – A meeting report
A B S T R A C T
The Human Papillomavirus (HPV) Prevention and Control Board convened a meeting in Bucharest, Romania (May 2018), to discuss the role of healthcare providers
(HCPs) in prevention programs, with a focus on HPV vaccination and cervical cancer screening. International and local experts discussed the role that HCPs can play
to increase the uptake of HPV vaccine and screening. Experts recommended: 1) increasing HCP norms of getting vaccinated; 2) training providers to make effective
recommendations; 3) making culturally appropriate materials available, in local languages; and 4) centralizing and coordinating education and information material,
to direct both HCPs and the general public to the best material available.
1. Introduction
The HPV Prevention and Control Board (www.hpvboard.org) or-
ganizes technical and country meetings, where international and local
experts exchange experiences and insights to strengthen countries’ ef-
forts to secure HPV prevention and control and discuss technical items
related to HPV prevention programs [1–4]. On May 15–16, 2018, the
fifth meeting in the series was held in Bucharest, Romania. This tech-
nical meeting targeted the role of healthcare providers in prevention
programs, with a focus on HPV vaccination and cervical cancer
screening. For the sake of clarity, we use two terms in this report:
healthcare providers (HCPs) and general practitioners (GPs). HCPs in-
cludes all people working in healthcare (e.g. physicians, nurses, phy-
sician assistants, but also technicians). GPs (sometimes called family
doctors) are physicians who focus on primary care at the outpatient
clinic or community level. Similarly, the terms confidence and hesi-
tancy are used in this report. Note that these are not synonyms: con-
fidence is an attitude that vaccines are good or bad (people can believe
both), whereas hesitancy is a motivation (or lack of it) related to getting
vaccinated or giving the vaccine.
2. The role of HCPs in the vaccination program
2.1. Lessons learned from influenza vaccination acceptance among HCPs
The rationale for vaccination of HCPs against seasonal influenza is
clear: 1) HCPs are at increased risk for occupational exposure to in-
fluenza [5]; 2) HCPs with influenza-like illness may continue to work,
placing patients (and colleagues) at risk [6,7]; 3) HCPs care for patients
at high-risk for serious morbidity, complications and death due to in-
trinsic factors such as age (neonates, elderly) or underlying health
conditions (e.g. immunosuppression or other chronic disease); 4) un-
vaccinated HCPs may be the source of infection in outbreaks, especially
in neonatal intensive care units [8–10]; 5) influenza vaccine is effective
in preventing influenza and absenteeism in HCPs, with absenteeism
leading to an increased workload for the remaining (vaccinated) HCPs
[11–15]; and 6) HCPs are role models for their patients [16]. Hence,
vaccination of HCPs is justified to directly protect HCPs, indirectly
protect their patients, colleagues and families, and to maintain optimal
healthcare services during the flu season. Nevertheless, influenza
vaccination rates among HCPs vary widely, ranging from<5%
to> 90% worldwide. In Europe, vaccination coverage among HCPs is
generally low (often less than 30%) despite recommendations. Influ-
enza vaccination coverage among HCPs in the United States (US) is
higher than in Europe and other countries [17].
Requiring influenza vaccination of hospital personnel in US hospi-
tals has led to a vaccination coverage of over 98% in this population
[18]. In Europe, acceptance of policies requiring vaccination for HCPs
ranges between 50% and 70%, with higher acceptance for HCP who
care for high-risk patients. Barriers to increasing coverage of influenza
vaccination among HCPs are similar to those that exist for the general
public, namely insufficient knowledge of, and misconceptions about,
vaccine safety and effectiveness, lack of awareness of vaccine re-
commendations, and mistrust of health authorities [19].
Given that HCPs often are trusted role models for their patients,
refusal of vaccination by HCPs may undermine vaccine uptake in the
general population. To increase vaccination among HCPs, several gen-
eral principles seem to apply: 1) Increase education of HCPs related to
vaccination and vaccines; 2) Emphasize the norms of vaccination (e.g.,
to protect patients, colleagues and family) among HCPs; and 3) Make it
easier for HCPs to get vaccinated (e.g. by making vaccines free of
charge, improving access to vaccination by supplying them at the work
space). When HCPs truly are hesitant, education will not always solve
these issues, in which case engagement is needed, as well as providing a
space to listen to and address their concerns.
2.2. Is there vaccine hesitancy among european HCPs?
HCPs are among the most trusted source of immunization in-
formation [20], and therefore are a core tool to address low or declining
public confidence in vaccination. However, reliance on HCPs to provide
optimal guidance to patients (the word patient reflecting all healthcare
users, including healthy (adolescent) individuals [21]) may be jeo-
pardized if HCPs, themselves, have doubts about vaccines or they do
not communicate effectively with their patients. HCPs, regardless of
their attitudes towards vaccination, may also delay or inappropriately
alter the vaccination schedule. A qualitative study of HCPs from four
different European countries (Croatia, France, Greece and Romania
[22]) showed that, while in general the benefits of vaccination were
appreciated, perceived risks played an important role in their attitudes
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towards vaccination. Concerns about possible side-effects, especially for
vaccines proposed for addition to the national immunization program
(such as HPV vaccine in Romania) were also raised, together with
questions about HCP's responsibility for these side-effects if they should
occur in their patients. Furthermore, the study found that HCPs some-
times mistrust pharmaceutical companies, and, albeit less frequently,
health authorities, especially in France and Greece. While some HCPs
see it as their role to respond to hesitancy and influence the patients'
decision, others feel they should remain neutral, and leave it to the
patients to decide. In general, HCPs felt that vaccine confidence could
be improved by providing more information to HCPs and their patients
(e.g., on side-effects), provider training (e.g., communication skills), as
well as stricter legislation (vaccination requirements, action against
vaccine-hesitant HCPs). Finally, it is clear from the study of these four
different countries [22], that while some elements appear across all
countries, most issues are country- and context-specific.
2.3. The role of HCPs in measles control and prevention in Bulgaria
During the 2009–2011 measles outbreak in Bulgaria, 90% of cases
occurred in the Roma population as a result of the accumulation of a
large susceptible population due to low measles-mumps-rubella (MMR)
vaccine coverage [23]. Between April 2009 and December 2010,
188,700 MMR vaccine doses were administered free of charge through
the routine immunization system and special outreach teams in colla-
boration with Roma health mediators (HMs), to specifically target
Roma communities. The HMs played a vital role in the success of this
campaign, which started in 2009 in the affected regions for persons of
Roma ethnicity and was extended to a national level, targeting persons
aged 13 months to 20 years who had not received two MMR vaccine
doses. From March 2010, persons aged 30 years and older who had not
received two MMR doses were targeted. HCPs were offered a dose of
MMR, regardless of their immunization status or age.
This outbreak helped develop and strengthen national and local
vaccination activities through enhanced collaboration between HCPs
and Roma organizations with the aim of improving the Roma com-
munity's integration into the healthcare system [24]. Bulgaria was one
of the first countries in the WHO EURO region to test the Guide to
Tailoring Immunization Programs (TIP) [25]. Bulgaria participated in
the European Centre for Disease Prevention and Control (ECDC) and
World Health Communication Associates (WHCA) project “Let's talk
about protection: an ECDC Action Guide to enhance childhood vacci-
nation uptake”, aiming to coordinate a group of experts to develop
content for an Action Guide on childhood immunization and different
vaccines, with a special focus on MMR vaccine, targeting health pro-
fessionals, parents/grandparents, underserved/poorly served popula-
tion and media. WHCA helped ECDC to facilitate the dissemination of
the Bulgarian version of the childhood vaccine uptake communication
action guide, by health care providers in selected communities in Bul-
garia as a central part of a pilot project initiative to increase MMR
vaccination uptake by underserved population groups.
A practical vaccination guide, adapted to the context in Bulgaria,
was published and distributed for use by HCPs and HMs [26].
2.4. Should we monitor HCPs’ attitudes towards vaccination?
Currently, limited activities are undertaken to try to understand and
measure HCPs' concerns about vaccines and immunization across
countries. The Vaccine Confidence Project's “2018 State of Vaccine
Confidence in the EU” report provides a clear correlation between
HCPs' attitudes regarding vaccination and those of their patients [27].
Patients trust HCPs, so if HCPs do not appear knowledgeable about the
pros and cons of the vaccine and confident in their recommendation,
the patients may opt to look for other, potentially less accurate, sources.
Optimally, measurement of vaccine confidence among HCPs should
be introduced into vaccination surveillance systems, together with the
collection of vaccine safety and effectiveness data. Ideally, assessment
of HCPs vaccine confidence could be achieved via routine periodic
surveys, respecting the country-specific context. To maximize response
rate, surveys would need to balance open-ended (non-leading) data
collection with data collection tools that take minimal time and are easy
to complete. An important objective would be to identify the existence
of, and reasons for, vaccine confidence in HCPs, as well as in the general
public.
While vaccine confidence among HCPs may be an important in-
dicator of vaccine confidence in the general population, other im-
portant measurements include provider behavior (recommendation)
and patient behavior (how often patients who want to delay or refuse
vaccination are encountered). Surveillance should also include HCPs'
reactions to parent hesitancy, e.g., how do HCPs follow-up with parents
who refuse a vaccine for their child? Further, it is important to identify
the questions HCPs may have about vaccination or about parent's and
patient's concerns, to be able to address them appropriately. Finally,
HCPs are no longer the only information source related to vaccination
and, as such, may be challenged by patients with information from
other, perhaps less reliable, sources [28,29].
Education of HCPs related to vaccination and communication is
essential to permit them to provide appropriate, accurate information
to parents.
3. The role of HCPs in implementing and expanding coverage of
HPV vaccination: country examples
3.1. Bulgaria: the role of health mediators in reaching the roma population
The Bulgarian National Network of Health Mediators was estab-
lished in 2007 to represent more than 200 HMs working in the field,
among the most marginalized people. Continuing education on im-
munizations is provided to members via regional and national meet-
ings. The HMs connect the GPs and the Regional Health Inspectorate to
the Roma community, actively searching for under-vaccinated children.
For example, during the measles epidemic in 2010, HMs, teaming up
with the Regional Health Inspections, managed to vaccinate more than
188,000 children. Similarly, the HPV prevention program is only suc-
cessful in regions where Regional Health Inspectorate, GPs and HMs
work closely together. In the Roma communities, HMs generally do not
encounter anti-vaccine sentiments, but challenges occur due to a lack of
information, poor communication, and access to GPs.
3.2. Scotland: school immunization teams and the HPV program
The Scottish HPV immunization program started in September
2008, as a school-based program targeting 12- and 13-year-old girls,
although a catch-up program for girls under 18 years old ran for three
years. For the first four years the bivalent vaccine was used and from
2012, the programme changed to the quadrivalent vaccine. Vaccine
uptake in the routine population was high, with around 90% of eligible
girls receiving all doses (Fig. 1), whereas uptake in the catch-up po-
pulation was much lower, around 65% receiving all doses [30].
These high routine vaccination rates with the bivalent HPV vaccine
led to a large reduction in prevalence of HPV vaccine types 16/18 (from
30% to 4.5%), and in HPV types 31/33/45 (from 14.2% to 2.6%),
whereas no impact was seen on other HPV types [30]. In recent years,
the role of school nurses in immunization has been taken over by
dedicated school immunization teams. These teams send out letters to
the schools in May with suggested vaccination dates, distribute consent
forms and information leaflets to schools in mid-November, and hold
HPV vaccination sessions between January and March. They have time
to establish and maintain a relationship with schools and parents, and
to increase awareness and understanding amongst girls. Vaccine uptake
rates have remained high, despite some growth in anti-vaccine senti-
ment, and attempts at coordinated anti-HPV campaigns [31].
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3.3. France: the role of HCPs in vaccination
Recent work has shown that France had the lowest vaccine con-
fidence in Europe [32,33]. However, French health barometer data,
which is based on telephone surveys, show that this low confidence
bottomed out in 2010, and has gone up again, although it has not
reached the pre-2010 level. A study has shown that people who trust
the health care system and health professionals were more likely to
have been vaccinated [34]. Furthermore, those who were advised by
HCPs to be vaccinated showed the intention to do so [34]. An HCP
recommendation, together with subjective norms, had the strongest
association with self-reported vaccination.
Vaccine confidence in France may be influenced by several trends: 1) a
general, increasing feeling of distrust toward governmental institutions
and, in particular, distrust of public health authorities; 2) the rise of
complementary and alternative medicines that promote the utilization of
“natural” means to tackle diseases, to the exclusions of vaccines; 3) the
impact of (non-evidence-based, anti-vaccine) information amplified
through social media, and 4) the indifference of global leaders to act upon
these trends. The combination of these phenomena may have facilitated
the rapid propagation of incorrect or suspicious information, which may
have affected acceptance of some vaccines.
3.4. Flanders (Belgium): training of medical students and vaccinators
At the University of Antwerp, medical students come across vaccine-
related topics throughout their curriculum, with applied training on
syringe and needle use in Bachelor year 1; an introduction to vacci-
nology, including skills training in Bachelor year 2; and a one-week
module on vaccinology in Bachelor year 3. In year 7, the first year of GP
training, a case-based update on vaccinology is provided. Training is
not restricted to medical students; a 12-h module on vaccinology is also
provided to pharmacy students. At the European level, together with
other universities, a two-year educational Master program has been
developed (EU-LIVE master course1). As a less intensive alternative, a
teaching week on infectious diseases and vaccines is organized at four
European universities, combined with a summer school program in
Paris (EU-IDEAL-course2).
The University of Antwerp also organizes a Summer School on
Vaccinology course3 for students, including topics on immunology,
public health, infectious diseases, vaccines, immunization programs,
vaccine safety communication with practical training on how to vac-
cinate. Finally, the University of Antwerp – with the support of the
Flemish Health Agency - organizes a yearly Valentine Vaccination
Symposium4 for vaccinators (doctors and nurses) with scientific pre-
sentations covering current vaccination topics relevant to the health-
care sector. In 15 years, the symposium has grown from less than 100 to
over 500 participants. To keep the topics as up-to-date as possible,
questions are requested from participants beforehand, and answered
during the symposium by an expert panel.
3.5. Flanders (Belgium): the flemish vaccination board
In Belgium, the inclusion of vaccines into the vaccination program is
based upon recommendations of the (federal) national immunization
technical advisory group. However, public health prevention efforts are
a regional responsibility and duty. In Flanders, vaccination advice is
provided by the Flemish Vaccination Board, which consists of members
representing all professionals involved in vaccination and academics.
The Vaccination Board advises about the implementation of the vac-
cination program, about communication and vaccination campaigns
and prepares common communications about vaccinations. In case of a
potential crisis, the Vaccination Board provides pro-active commu-
nication (in one voice) to vaccinators and the Minister of Health.
3.6. Colombia: the role of the HCP/specialist after a mass psychogenic event
Although several key epidemiological studies on the relationship
between HPV and cervical cancer and phase 3 efficacy trials of the HPV
vaccines were conducted in Colombia [35–40], at the time of HPV
vaccine introduction, confusion about the vaccine was high among both
Fig. 1. Uptake of completed course of HPV immunizations by the end of school years 2009/10 to 2017/18 in Scotland (source [29]).
1 http://live.univ-lyon1.fr/.
2 https://www.ideal-program.com/i3dc.html.
3 https://www.uantwerpen.be/en/summer-schools/vaccinology/.
4 https://www.uantwerpen.be/nl/onderzoeksgroep/cev/valentijn-
vaccinatie/.
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GPs and parents. The intense communication campaign for the in-
troduction was not supported by providing information and education
to those responsible for administration of the vaccine, leaving them
unprepared for questions from the public. Hence, following the launch
of the HPV vaccination program in 2012, Colombia was not prepared
for the crisis that happened in Carmen de Bolivar in 2014, when 15 girls
from one school presented with tachycardia, shortness of breath, chest
pain, paresthesia and fainting. An outbreak study involving 517 girls
ruled out that the events were vaccine-related, but the response to the
crisis was too slow and technical and lacked empathy for the affected
girls and parents. In contrast, the anti-vaccine movement was well-or-
ganized and quick to respond. Vaccine confidence was further eroded
by the request from the National Academy of Medicine to the Minister
of Health to screen for, and exclude girls with autoimmune conditions,
or a family history of such conditions from vaccination. This crisis, and
the follow-up actions, led to a sharp decline in HPV vaccine coverage
from 88% in 2012 to 14% in 2016. (Fig. 2)
To increase HPV vaccine advocacy, a roundtable has been estab-
lished (including the Liga Colombiana contra el Cancer, the Ministry of
Health, and Clinical Societies) to improve cervical cancer control
through HPV vaccination and introduction of HPV testing as a primary
screening test. Furthermore, an e-course on HPV vaccine efficacy and
safety has been developed by the Catalan Institute of Oncology and the
National Cancer Institute of Colombia targeting Colombian physicians
and HCPs. Together with the HPV Prevention and Control Board, a
statement was issued to refute the proposal to screen all vaccine re-
cipients before immunization (December 2017). Finally, in some cities
(Cali and Pasto), school-based HPV vaccination will be reactivated.
In May 2018, Colombian media paid attention to the Cochrane re-
port on the safety of HPV vaccines [41], which was the first positive
media coverage on HPV since the crisis and may prove to be a turning
point for HPV vaccination in Colombia. To boost vaccine coverage, the
next country meeting of the HPV Prevention and Control Board was
scheduled in Colombia, in November 2018.
4. Strategies to enhance the impact of HCPs in improving HPV
vaccination coverage
4.1. Making effective HPV vaccine recommendations
Patient-provider communication is key to ensuring a successful HPV
vaccination program and optimal coverage rates. There is a clear need
for improved strategies to communicate valid information concerning
HPV vaccines, especially in countries that provide the vaccine through
clinics or GPs. In the US, challenges to routine recommendation include
that many HCPs expect conversations about HPV vaccine for adoles-
cents will be uncomfortable, believe that parents do not want the
vaccine for their children, and think that the discussion will take a long
time. Hence, HCPs often discuss HPV vaccination at the end of a con-
sultation, or not at all [42].
In addition, a key factor in HPV vaccine uptake is the strength of the
HCPs' recommendation: in a nationally representative study, only 35%
of children without a HCP recommendation were vaccinated, while
65% with a HCP recommendation received the vaccine [43]. Pre-
sumptive announcements are effective in increasing uptake, but pro-
viders rarely make announcements (1.5% of visits) [44]. This finding
led to the development of ‘the Announcement Approach.’ For all fa-
milies, the provider states that three vaccines will be provided at the
end of the consultation, mentioning HPV vaccine in the middle. If the
parent is hesitant, the provider asks for the main concern, addresses it
and ends with a strong recommendation. In a randomized controlled
trial, the announcement training improved HPV vaccine uptake, both in
girls and boys [45]. Furthermore, the HCPs were satisfied with the
approach, as they felt that it was both easier for parents and for HCPs. A
different training, based on open-ended patient-directed conversations,
led to no improvement in HPV vaccine coverage [45].
Based on these findings, the announcement approach was further
refined and is now: Announce + Connect, Clarify, Counsel. Messages
for the Clarify step were obtained from a review of online materials and
interviews with providers and then tested with US parents [46].
4.2. Working with media: helping HCPs to address HPV queries
The first step towards working with media is the realization that
media work differently from healthcare or science: they have their own
deadlines, headlines, sources and influencers. When interacting with
the media, HCPs should be prepared: know how HPV is being covered
in the news and social media; understand the main themes and argu-
ments presented on various sides of the issue; and be aware of the gaps
in stories, facts, or perspectives that could help improve the support for
HPV vaccination. Furthermore, HCPs are advised to develop effective
communication skills to avoid common pitfalls. It is important to build
Fig. 2. HPV Vaccine Coverage in Colombia (based on data provided by professor Munoz).
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relationships with the media (if they know you in times of peace, they
may turn to you first in times of crisis). One must strive for evidence-
based communication, get your facts right, while keeping in mind that
cultural adaptation of materials may be necessary. It is important to
help HPV vaccine advocates tell their stories and then amplify messages
through social media. Another important strategy is to be opportunistic
by linking in HPV vaccination information to important events, taking
advantage of breaking news, and providing key information when the
target population may be receptive. Communication with the media
should always be based on mutual respect and ethical communication
standards.
4.3. The value of training for HCPs
As stated previously, HCPs are an important source of immunization
information. National vaccination programmes in England are sup-
ported by a series of cross-sectional surveys exploring attitudes to the
infant and teenager immunization programmes [47,48]. The 2017
surveys showed that parental confidence in their decision to immunize
their child was increased following discussion with HCPs. Additionally,
16% of parents who planned not to immunize their child and 27% of
parents who were previously undecided, decided to immunize after
talking to an HCP. The information provided by HCPs is well-trusted
and, when immunization programs are supported by HCPs, confidence
is heightened. Fewer than 10% parents and teenagers reported having
come across information that would make them concerned about any
teenage vaccination. The small number of those with any concerns were
more likely to have seen this online. Only 10% of parents and 7% of
teens reported getting any immunization information online. Ninety
three percent of teenagers trusted immunization advice given by health
professionals [48]. This compares to only 17% who reported that they
would trust immunisation information on social media. [Joanne Yar-
wood, personal communication, data submitted for publication, re-
ference will be updated once accepted].
At the same time, HCPs feel more confident in giving advice when
they receive appropriate training, indicating the importance of appro-
priate training of HCPs [49]. Therefore, it is essential to ensure that all
those delivering immunizations are well trained and confident when
providing immunization information. Recently, in the UK, the national
minimum standards and core curriculum for immunization training,
which describes the training for all registered HCPs involved in im-
munization, has been revised through a consultative process [50].
Furthermore, a new e-learning program has been developed covering
topics such as: the national immunization policy; immunology; vaccine
preventable diseases; communication with patients and parents; legal
aspects; vaccine storage and administration [Joanne Yarwood, personal
communication].
5. Strengths and weaknesses of different school and GP-based HPV
vaccination programs
School-based and GP-based HPV vaccination programs are used
extensively world-wide.
Several strengths of school-based vaccination programs have been
defined [51–53]: the ease to distribute and collate information within
the school environment; the cost-effectiveness of having many vacci-
nees in the same place; and given the well-defined number of vaccinees
in each setting, vaccine uptake is easy to calculate. Furthermore, chil-
dren, including pre-adolescents in secondary school, are a captive au-
dience in their classrooms, potentially leading to higher uptake. Simi-
larly, because students are among friends, vaccination may turn into a
shared experience, again potentially leading to higher uptake. As a
weakness, this group setting may turn against the program, because
vaccination of groups may be more prone to mass psychogenic illness,
e.g. fainting, especially if the actual vaccination process is witnessed by
the peers. This is particularly the case in adolescent age groups, and less
in pre-teen age groups: a recent systematic review described eight
clusters of anxiety-related adverse events following immunization
(AEFI) occurring in both rural and urban settings, as well as in high-,
middle- and low-income countries. Among the patients, males and fe-
males were affected equally, and seven out of eight clusters occurred in
school-aged population, with 6 out of 7 occurring in 12–17-year-olds
[54]. Another possible weakness is parents’ concerns about giving up
their control [Emilie Karafillakis, personal communication]. Other
weaknesses of school-based vaccination programs include the need for a
centralized database for tracking vaccinations, and possible shortage of
appropriately trained personnel, especially in settings requiring im-
munizations to be given by HCPs. Finally, school-based vaccination
programs may not reach all children, particularly in countries where
school is not compulsory, but also for children not attending compul-
sory school.
The major strength of the GP-based program is the personal re-
lationship between the GP and the vaccinees and their parents; the GP
knows the child and the family and has insight into their medical his-
tory. Weaknesses of a GP-based program include the need for a cen-
tralized, national database for tracking vaccinations, similar to the
school-based program; the fact that the patient must visit the GP to get
vaccinated – healthy people may not visit their GP on a regular basis;
vaccine uptake is more difficult to calculate; and the GP-based system is
sub-optimal for reaching underserved groups (although this can be re-
medied by health mediators as shown in Bulgaria). Finally, a major
weakness is vaccine-hesitant GPs, which may affect vaccination of all
patients in the practice.
Other vaccine delivery programs do exist, such as clinic-based
programs. The main weakness of clinic-based programs is that the HPV
vaccination rates are lower in countries with clinic-based provision. In
countries using both systems, such as Canada [55], or the UK, early in
the program [56], rates are lower in clinics than in school programs.
Other vaccine delivery programs were not specifically discussed.
6. Information and training materials
6.1. US centers for disease control and prevention (CDC)
The US CDC has a web portal on HPV,5 directed towards parents,
HCPs and partner organizations. To support clinicians, factsheets have
been developed: addressing the 2-dose topic; providing specific vaccine
information; and “tips and timesavers,” helping clinicians to provide
parents with the clearest answers to their HPV questions.
To allow clinicians to see and hear fellow clinicians talk about HPV
and HPV vaccination, an online series of videos called
#HowIRecommend,6 is available and others are in development.
Slide decks with information on the burden of disease, HPV vaccine
recommendations and effective communication with parents are
available to anyone who would like to use it, as well as web-on-demand
continuing education courses for immunization providers. Finally, a
#preteenvaxscene webinar series7 has been produced on a variety of
topics related to increasing the use of recommended vaccines in pre-
teens and teens.
6.2. European Centre for Disease Prevention and Control (ECDC)
The ECDC8 provides a wealth of material, including communication
guides and publications on general immunization, vaccine hesitancy,
cultural adaptation of communication materials and vaccine-specific
5 https://www.cdc.gov/hpv/index.html.
6 https://www.cdc.gov/hpv/hcp/how-I-recommend.html.
7 https://www.cdc.gov/hpv/preteenvaxscene-webinar.html.
8 https://ecdc.europa.eu/en/home.
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material. A communication toolkit,9 aiming to increase immunization
uptake, provides template materials. Finally, infographics and brochure
on a range of vaccination-related topics are also available.
6.3. World health organization, regional office for europe (WHO/Europe)
Within the vaccine-preventable diseases and immunization program
(VPI), WHO-Europe established an informal HPV peer group of im-
munization managers from Austria, Denmark, France, Ireland,
Netherlands, Sweden and the United Kingdom, who participate in bi-
monthly teleconferences and semi-annual face-to-face meetings to share
lessons learned, advise each other and discuss the latest evidence on
HPV. VPI also developed supporting materials, including a series of
HPV videos10 and a comprehensive HPV ‘questions and answers’
package11 segmented by key target audiences.
Furthermore, in 2017, VPI provided comprehensive support and
worked closely with three Member States in the region which were
introducing the HPV vaccine: Armenia, Georgia and the Republic of
Moldova. This support included formative research, in-depth interviews
and focus groups to identify barriers and enablers relevant to the in-
troduction of the HPV vaccine. This support also identified possible
communication channels, trusted sources and development of key
messages related to the vaccination program which resulted in the
development of a field guide that was piloted by the three member
states upon introduction of the HPV vaccine. The use and usefulness of
the guide was evaluated, and based on encouraging results, the field
guide was consequently revised into a tool for new vaccine introduction
in general.
An online library with more than 20 supporting documents for
building vaccination confidence and responding to crisis is available
from WHO-Europe. The package consists of a “vaccination and trust”
background document; support documents; and a training program12.
Finally, training modules are available for HCPs on vaccine safety
and contraindications13 to prepare confident key trainers and provide
training materials to educate front line HCPs. Topics included in the
modules are: monitoring of vaccines' safety during pre-and post-li-
censure periods; WHO recommendations on contraindications and
supporting evidence; the basics of AEFI classification and causality as-
sessment; and routine and new vaccines’ impact assessment.
6.4. The Catalan Institute of Oncology online oncology community
E-oncologia14 is the virtual oncology training program of the Cat-
alan Institute of Oncology, with 71 courses and 2300 hours of training
materials, currently in nine languages. One part of the program is de-
voted to cervical cancer prevention. This module is endorsed by the
International Federation of Gynecology and Obstetrics, the Interna-
tional Atomic Energy Agency, the Unions for International Cancer
Control, the International Agency for the Research on Cancer and the
WHO. The module is fully online, with three moderated forum discus-
sions on epidemiology and natural history, vaccination and screening.
As trainees can become tutors, a snowball effect in training is
envisioned. The module can be calibrated to local needs, such as an
adapted course for Colombia after the vaccine crisis. As described
earlier, the HCP educational needs during the Colombian crisis were
addressed by the e learning program at ICO/NCI in Bogota. Within the
first three months of offering the course, over 4000 HCP (GPs, nurses,
midwifes, etc.) in Colombia participated. The course has national tu-
tors, who are ready to address any questions.
Furthermore, translation of the course into new languages is pos-
sible, as is currently ongoing for a Greek translation. In order to con-
tribute to the education of HCPs in Greece and subsequently to the
promotion of vaccination and screening among Greek women, the
Hellenic HPV Society decided to collaborate with ICO to translate the
online cervical cancer prevention course.
6.5. Other resources
- The US National HPV Vaccination Roundtable provides a short
video, explaining the association between HPV and head and neck
cancers. This video can be used at staff meetings or conferences.
Furthermore, clinician and systems action guides, as well as, a
school nurse toolkit have been developed.15
- The American Academy of Pediatrics has developed a toolkit16 to
help clinicians educate other HCPs; discuss HPV vaccination with
parents; and make necessary changes to improve HPV vaccination
rates. They also provide a Nurse Tip Sheet, a 2-page vaccination
resource for primary care nurses.
- The American Cancer Society has developed a “Steps” guide17 for
increasing HPV vaccination, including a toolkit, a road map and a
portal with resources.
- Vaccine makers also often have educational material available on
their websites.
6.6. Discussion
While many resources are available, further needs were raised
during the meeting, especially related to the need for answers to spe-
cific, frequently asked questions in a Q&A format targeting vaccines,
parents and HCPs. This material should be in plain language and easy to
comprehend, but with high-quality and evidence-based information, to
circumvent concerns from escalating and ultimately to increase vaccine
uptake. The information should be country-specific, which goes beyond
simple translation, as the message should ideally be locally and cultu-
rally adapted [57].
Because of the important role of HCPs, they should be given time to
study through continuing (medical) education, with support from their
professional societies. Many forms of training should be offered, in-
cluding face-to-face settings, webinars, e-learning courses, conferences
and peer-to-peer learning, so HCPs can choose the most appropriate
form for themselves, and feel more comfortable in addressing the sub-
ject of HPV vaccination. In addition, efforts should be made to train
current medical and paramedical students on vaccinology, as they are
the health care providers of the future.
As many resources are already available, it is important not to re-
invent the wheel, and to learn from what has already been created. But
it might be useful to review and rank the available resources, and make
sure that the best resources are available in several languages, to reach
a broad public, in a one-stop shop.
9 https://ecdc.europa.eu/en/publications-data/communication-toolkit-
immunisation-how-increase-immunisation-uptake.
10 http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-
and-immunization/vaccine-preventable-diseases/human-papillomavirus-hpv2.
11 http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-
and-immunization/publications/2017/questions-and-answers-about-hpv.-
facts-about-the-virus-and-the-vaccine-2017.
12 http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-
and-immunization/publications/vaccination-and-trust-library.
13 http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-
and-immunization/publications/2017/training-manual-vaccine-safety-and-
false-contraindications-to-vaccination-2017.
14 http://www.e-oncologia.org.
15 http://hpvroundtable.org/resource-library/.
16 https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/
immunizations/HPV-Champion-Toolkit/Pages/HPV-Champion-Toolkit.aspx.
17 https://www.cancer.org/health-care-professionals/hpv-vaccination-
information-for-health-professionals.html.
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7. Lessons learned
The burden of addressing public vaccine hesitancy is increasingly
being placed on HCPs. However, it is easy to forget that HCPs are also
members of the public: they can have the same questions, the same
doubts, and the same fears about vaccines as their patients have. This is
of greater importance for HCP with specializations not traditionally
involved in vaccinations (e.g. obstetricians and gynecologists).
Insufficient communication, engagement and education of HCPs related
to vaccination can jeopardize vaccine uptake and attempts at improving
public confidence. To address this, it is essential to take the time to
actively listen to HCPs’ concerns about vaccination. HCPs need more
support to manage the changes in society (more assertive patients, ac-
tively seek information, which is not always scientifically correct) as
well as the quickly evolving vaccine environment, through training,
incorporation of vaccinology into the medical curriculum, providing
access to tools and resources. Those involved in vaccine program design
and implementation need to rebuild trust among HCPs by including
them at the earliest possible stage: in decision making for vaccine re-
commendations and policies, as well as the design of communication
materials. Finally, as vaccinated HCPs are more likely to recommend
vaccination to their patients, there is a need to restore and maintain
vaccination as a norm among the health community: the HCP as role
model.
HCPs can be trained to use the announcement approach to increase
HPV vaccination uptake. The approach should be: Announce, (and only
if parents hesitate) Connect, Clarify, Counsel, while keeping in mind
that parents who say no, may say yes later. Therefore, vaccination
should be brought up again at each successive visit.
Education and information material is available from many sources,
but centralization and coordination of these materials might be useful,
to direct both HCPs and the general public to the best material avail-
able.
Consistent introduction of vaccinology into the medical and para-
medical curriculum should be pursued. In general, the focus in training
is still too much on cure, and not enough on prevention. The apparent
lack of training on vaccinology during the curriculum can be remedied
through summer courses, and later with inclusion of modules on vac-
cinology. Post-academic training can be provided through symposia for
vaccinators (e.g., Flemish Valentine Vaccination symposia). This pro-
vides an opportunity to discuss questions and possible concerns, while a
survey of these questions may provide insight into vaccine confidence
locally.
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